Aethlon Medical's Upcoming Conference Call Announced
Aethlon Medical's Upcoming Conference Call Announcement
Aethlon Medical, Inc. (NASDAQ: AEMD), a pioneering medical therapeutic company dedicated to developing innovative products aimed at combating cancer and critical infectious diseases, has made an important announcement regarding its forthcoming financial results. The company is slated to release its financial data for the fiscal fourth quarter, which ended March 31, 2025, on June 26, 2025, at 4:15 p.m. Eastern Time.
Conference Call Details
Following the financial results release, Aethlon Medical management will lead a conference call at 4:30 p.m. Eastern Time on the same day. During this session, they will discuss key financial metrics and shed light on recent corporate developments. Participants will have the opportunity to engage in a question-and-answer segment following the management team's remarks, allowing stakeholders to gain insights into the company's performance and strategic direction.
How to Participate
To participate in the conference call, interested individuals can register in advance. After registering, participants will receive a unique dial-in number for the session. For those who may not have internet access or prefer to join without prior registration, Aethlon Medical has provided a toll-free dial-in number for U.S.-based participants: 1-844-836-8741. International calls can be made to 1-412-317-5442.
Replay Availability
Aethlon Medical understands that not everyone may be able to attend the live call. Consequently, a replay will be accessible approximately one hour after the call concludes and will remain available through July 26, 2025. Participants can listen to the replay via Aethlon Medical's website, or by calling 1-877-344-7529 for domestic calls, and 1-412-317-0088 for international, with a Canada toll-free option at 1-855-669-9658. The designated conference ID number for the replay is 4903201.
About Aethlon Medical and the Hemopurifier
Aethlon Medical is at the forefront of developing breakthrough therapeutic solutions, particularly the Hemopurifier. This clinical-stage immunotherapeutic device is specifically engineered to address cancer and severe viral infections, including its applications in organ transplantation. Evidence from human studies has indicated that the Hemopurifier can effectively remove life-threatening viruses, while pre-clinical studies have showcased its ability to eliminate harmful exosomes from biological fluids. Such removal holds significant promise in cancer treatment, where exosomes can contribute to immune suppression and metastasis, along with managing life-threatening infectious diseases.
The Hemopurifier has received recognition from the U.S. Food and Drug Administration (FDA) as a designated Breakthrough Device. This designation applies to individuals suffering from advanced or metastatic cancer who have either not responded to or cannot tolerate standard treatment options. Moreover, the device also possesses an open Investigational Device Exemption (IDE) application regarding its utility against life-threatening viruses not adequately addressed by existing therapies.
Company Contact Information
For further inquiries, Jim Frakes serves as the Chief Executive Officer and Chief Financial Officer of Aethlon Medical, Inc.
Investor Relations
Investors and stakeholders wishing to connect further can reach out to Susan Noonan at S.A. Noonan Communications, LLC for detailed investor communications.
Frequently Asked Questions
What is the purpose of the upcoming conference call?
The conference call aims to discuss Aethlon Medical's financial results for the fourth quarter and provide updates on recent company developments.
How can participants join the call?
Participants can register online to receive a unique dial-in number or call in using the provided toll-free numbers for participants.
When will the financial results be released?
Financial results for the fiscal fourth quarter will be released on June 26, 2025, at 4:15 p.m. ET.
Will there be a replay of the conference call?
Yes, a replay of the conference call will be available approximately one hour after it ends, accessible until July 26, 2025.
What is the Hemopurifier?
The Hemopurifier is Aethlon Medical's innovative clinical-stage device designed to combat cancer and serious viral infections, showing potential to remove harmful exosomes and pathogens from the body.
About The Author
Contact Thomas Cooper privately here. Or send an email with ATTN: Thomas Cooper as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.